TY - JOUR AU - Cortazar, P. AU - Zhang, L. AU - Untch, M. PY - 2014 DA - 2014// TI - Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(13)62422-8 DO - 10.1016/S0140-6736(13)62422-8 ID - Cortazar2014 ER - TY - JOUR AU - Groheux, D. AU - Giacchetti, S. AU - Moretti, J. -. L. PY - 2011 DA - 2011// TI - Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer JO - Eur J Nucl Med Mol Imaging VL - 38 UR - https://doi.org/10.1007/s00259-010-1640-9 DO - 10.1007/s00259-010-1640-9 ID - Groheux2011 ER - TY - JOUR AU - Humbert, O. AU - Berriolo-Riedinger, A. AU - Cochet, A. PY - 2014 DA - 2014// TI - Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer JO - Eur J Nucl Med Mol Imaging VL - 41 UR - https://doi.org/10.1007/s00259-013-2616-3 DO - 10.1007/s00259-013-2616-3 ID - Humbert2014 ER - TY - JOUR AU - Aogi, K. AU - Kadoya, T. AU - Sugawara, Y. PY - 2015 DA - 2015// TI - Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer JO - Breast Cancer Res Treat VL - 150 UR - https://doi.org/10.1007/s10549-015-3303-9 DO - 10.1007/s10549-015-3303-9 ID - Aogi2015 ER - TY - JOUR AU - Groheux, D. AU - Sanna, A. AU - Majdoub, M. PY - 2015 DA - 2015// TI - Baseline tumor 18 F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+/HER2- breast cancer JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.115.154138 DO - 10.2967/jnumed.115.154138 ID - Groheux2015 ER - TY - JOUR AU - Hatt, M. AU - Groheux, D. AU - Martineau, A. PY - 2013 DA - 2013// TI - Comparison between 18 F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.112.108837 DO - 10.2967/jnumed.112.108837 ID - Hatt2013 ER - TY - JOUR AU - Groheux, D. AU - Hatt, M. AU - Hindié, E. PY - 2013 DA - 2013// TI - Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.28020 DO - 10.1002/cncr.28020 ID - Groheux2013 ER - TY - JOUR AU - Groheux, D. AU - Majdoub, M. AU - Sanna, A. PY - 2015 DA - 2015// TI - Early metabolic response to neoadjuvant treatment: FDG PET/CT criteria according to breast cancer subtype JO - Radiology VL - 277 UR - https://doi.org/10.1148/radiol.2015141638 DO - 10.1148/radiol.2015141638 ID - Groheux2015 ER - TY - JOUR AU - Soussan, M. AU - Orlhac, F. AU - Boubaya, M. PY - 2014 DA - 2014// TI - Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0094017 DO - 10.1371/journal.pone.0094017 ID - Soussan2014 ER - TY - JOUR AU - Son, S. H. AU - Kim, D. -. H. AU - Hong, C. M. PY - 2014 DA - 2014// TI - Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-585 DO - 10.1186/1471-2407-14-585 ID - Son2014 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. H. AU - Schwartz, J. N. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2775 DO - 10.1200/JCO.2006.09.2775 ID - Wolff2007 ER - TY - JOUR AU - Daisne, J. -. F. AU - Sibomana, M. AU - Bol, A. PY - 2003 DA - 2003// TI - Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms JO - Radiother Oncol VL - 69 UR - https://doi.org/10.1016/S0167-8140(03)00270-6 DO - 10.1016/S0167-8140(03)00270-6 ID - Daisne2003 ER - TY - JOUR AU - Wahl, R. L. AU - Jacene, H. AU - Kasamon, Y. PY - 2009 DA - 2009// TI - From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors JO - J Nucl Med VL - 50 UR - https://doi.org/10.2967/jnumed.108.057307 DO - 10.2967/jnumed.108.057307 ID - Wahl2009 ER - TY - JOUR AU - Orlhac, F. AU - Soussan, M. AU - Maisonobe, J. -. A. PY - 2014 DA - 2014// TI - Tumor texture analysis in 18 F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis JO - J Nucl Med VL - 55 UR - https://doi.org/10.2967/jnumed.113.129858 DO - 10.2967/jnumed.113.129858 ID - Orlhac2014 ER - TY - JOUR AU - Tixier, F. AU - Hatt, M. AU - Rest, C. C. PY - 2012 DA - 2012// TI - Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18 F-FDG PET JO - J Nucl Med VL - 53 UR - https://doi.org/10.2967/jnumed.111.099127 DO - 10.2967/jnumed.111.099127 ID - Tixier2012 ER - TY - JOUR AU - Cook, G. J. R. AU - O’Brien, M. E. AU - Siddique, M. PY - 2015 DA - 2015// TI - Non-small cell lung cancer treated with erlotinib: heterogeneity of (18)F-FDG uptake at PET-association with treatment response and prognosis JO - Radiology VL - 276 UR - https://doi.org/10.1148/radiol.2015141309 DO - 10.1148/radiol.2015141309 ID - Cook2015 ER - TY - JOUR AU - Schwarz-Dose, J. AU - Untch, M. AU - Tiling, R. PY - 2009 DA - 2009// TI - Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18 F]fluorodeoxyglucose JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.17.2650 DO - 10.1200/JCO.2008.17.2650 ID - Schwarz-Dose2009 ER - TY - JOUR AU - Specht, J. M. AU - Kurland, B. F. AU - Montgomery, S. K. PY - 2010 DA - 2010// TI - Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-0026 DO - 10.1158/1078-0432.CCR-10-0026 ID - Specht2010 ER - TY - JOUR AU - Cancello, G. AU - Maisonneuve, P. AU - Rotmensz, N. PY - 2013 DA - 2013// TI - Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mds430 DO - 10.1093/annonc/mds430 ID - Cancello2013 ER - TY - JOUR AU - Loibl, S. AU - Volz, C. AU - Mau, C. PY - 2014 DA - 2014// TI - Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma JO - Breast Cancer Res Treat VL - 144 UR - https://doi.org/10.1007/s10549-014-2861-6 DO - 10.1007/s10549-014-2861-6 ID - Loibl2014 ER - TY - JOUR AU - Adachi, Y. AU - Ishiguro, J. AU - Kotani, H. PY - 2016 DA - 2016// TI - Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2275-4 DO - 10.1186/s12885-016-2275-4 ID - Adachi2016 ER - TY - JOUR AU - Tateishi, U. AU - Miyake, M. AU - Nagaoka, T. PY - 2012 DA - 2012// TI - Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment JO - Radiology VL - 263 UR - https://doi.org/10.1148/radiol.12111177 DO - 10.1148/radiol.12111177 ID - Tateishi2012 ER - TY - JOUR AU - Groheux, D. AU - Giacchetti, S. AU - Espié, M. PY - 2011 DA - 2011// TI - Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET/CT: defining a clinical aim JO - Eur J Nucl Med Mol Imaging VL - 38 UR - https://doi.org/10.1007/s00259-010-1660-5 DO - 10.1007/s00259-010-1660-5 ID - Groheux2011 ER - TY - JOUR AU - Groheux, D. AU - Giacchetti, S. AU - Hatt, M. PY - 2013 DA - 2013// TI - HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.469 DO - 10.1038/bjc.2013.469 ID - Groheux2013 ER - TY - JOUR AU - Gebhart, G. AU - Gámez, C. AU - Holmes, E. PY - 2013 DA - 2013// TI - 18 F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.112.119271 DO - 10.2967/jnumed.112.119271 ID - Gebhart2013 ER - TY - JOUR AU - Groheux, D. AU - Mankoff, D. AU - Espié, M. PY - 2016 DA - 2016// TI - (18)F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials JO - Eur J Nucl Med Mol Imaging VL - 43 UR - https://doi.org/10.1007/s00259-015-3295-z DO - 10.1007/s00259-015-3295-z ID - Groheux2016 ER - TY - JOUR AU - Dunnwald, L. K. AU - Gralow, J. R. AU - Ellis, G. K. PY - 2008 DA - 2008// TI - Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.4385 DO - 10.1200/JCO.2007.15.4385 ID - Dunnwald2008 ER - TY - JOUR AU - Kruchten, M. AU - Vries, E. G. E. AU - Brown, M. PY - 2013 DA - 2013// TI - PET imaging of oestrogen receptors in patients with breast cancer JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70292-4 DO - 10.1016/S1470-2045(13)70292-4 ID - Kruchten2013 ER -